Alpha-Interferon Therapy and Cutaneous Vascular Lesions
Authors: Brigitte Dreno, Alain Huart, Eric Billaud, Pierre Litoux, Wandrille Y. Godefroy
Journal: Annals of Internal Medicine (1989)

Letters and Corrections1 July 1989Alpha-Interferon Therapy and Cutaneous Vascular LesionsBrigitte Dreno, MD, Alain Huart, MD, Eric Billaud, MD, Pierre Litoux, MD, Wandrille Y. Godefroy, MDBrigitte Dreno, MDSearch for more papers by this author, Alain Huart, MDSearch for more papers by this author, Eric Billaud, MDSearch for more papers by this author, Pierre Litoux, MDSearch for more papers by this author, Wandrille Y. Godefroy, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-111-1-95_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor: Recent in-vitro studies (1) have suggested that interferons may inhibit endothelial cell proliferation, and in-vivo regression has also been reported during long-term therapy with α-interferon in Kaposi sarcoma (2). Interferon appears to act not only by affecting endothelial cells directly but also by enhancing angiogenesis inhibitors or modulating the signals inducing angiogenesis (1).Contrary to these results, we have noted the development of cutaneous vascular lesions with punctate telangiectasias (3 to 8 mm in diameter) in 18 patients of 44 patients treated with interferon-α2a (18 X 106U daily for 2 months, then 12 X 106U...References1. SidkyNorden YE. Inhibition of angiogenesis by interferon: effects on tumor- and lymphocyte-induced vascular responses. Cancer Research. 1981;47:5155-61. Google Scholar2. MayerSilvaStalder DAR. Disseminated Kaposi's sarcoma in AIDS. Histogenesis-related populations and influence of long-term treatment with rIFN αA. J Invest Dermatol. 1987;89:618-24. CrossrefMedlineGoogle Scholar3. MiossecZiff PM. Immune interferon enhances the production of interleukin 1 by human endothelial cells stimulated with lipopolysaccharide. J Immunol. 1986;137:2848-52. MedlineGoogle Scholar4. WilsonWestau CJ. Activation of neonatal and adult human macrophages by alpha, beta and gamma interferons. Infect Immun. 1985;49:351-6. CrossrefMedlineGoogle Scholar5. LibbyWarnerFriedman PSG. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest. 1988;81:487-98. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Lab. Lilly Paris France PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByEffets cutanéo-muqueux indésirables des cytokines et des nouvelles molécules anticancéreusesEffets cutanés indésirables des chimiothérapies antitumorales et des cytokinesLivedo reticularis associated with interferon alpha therapy in two melanoma patientsEfectos cutáneos adversos de la quimioterapia antineoplásica y de las citocinasRéactions cutanées ou nécrose à l’interféron alpha : peut-on reprendre l’interféron ? À propos de six casCutaneous reactions to recombinant cytokine therapy 1 July 1989Volume 111, Issue 1Page: 95-96KeywordsAngiogenesisCell proliferationEndothelial cellsInterferonsKaposi sarcomaLesions Issue Published: 1 July 1989 PDF DownloadLoading ...